328 related articles for article (PubMed ID: 32936674)
21. A new targeted treatment for patients with a germline
Verdaguer H; Acosta D; Macarulla T
Future Oncol; 2020 Nov; 16(33):2691-2700. PubMed ID: 32799562
[TBL] [Abstract][Full Text] [Related]
22. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
Singh RR; Goldberg J; Varghese AM; Yu KH; Park W; O'Reilly EM
Cancer Treat Rev; 2019 May; 75():27-38. PubMed ID: 30927677
[TBL] [Abstract][Full Text] [Related]
23. Posttranscriptional Regulation of
Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
[TBL] [Abstract][Full Text] [Related]
24. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
25. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT
Cells; 2020 Apr; 9(4):. PubMed ID: 32276472
[TBL] [Abstract][Full Text] [Related]
26. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
Chapin WJ; Reiss KA
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
[TBL] [Abstract][Full Text] [Related]
27. An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor.
Borazanci E; Korn R; Liang WS; Guarnieri C; Haag S; Snyder C; Hendrickson K; Caldwell L; Von Hoff D; Jameson G
Oncologist; 2020 Jan; 25(1):e60-e67. PubMed ID: 31391296
[TBL] [Abstract][Full Text] [Related]
28. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
29. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
[TBL] [Abstract][Full Text] [Related]
30. What is the role of PARP inhibitors in pancreatic cancer?
Halder R; Shroff RT
Expert Rev Anticancer Ther; 2020 Nov; 20(11):913-918. PubMed ID: 32865047
[No Abstract] [Full Text] [Related]
31. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
32. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
33. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
34. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.
Golan T; Javle M
J Natl Compr Canc Netw; 2017 Aug; 15(8):1063-1069. PubMed ID: 28784866
[TBL] [Abstract][Full Text] [Related]
35. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Lee EK; Matulonis UA
Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
37. The role of PARP inhibitors in
Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
[TBL] [Abstract][Full Text] [Related]
38. Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline
Pimenta JR; Ueda SKN; Peixoto RD
Case Rep Oncol; 2020; 13(2):904-910. PubMed ID: 32884538
[TBL] [Abstract][Full Text] [Related]
39. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
40. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
